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Preeclampsia (PreE) refers to a syndrome charac-
terized by the new onset of hypertension and protein-
uria after 20 weeks of pregnancy in a previously nor-
motensive woman.  Preeclampsia affects 5-7% of all 
pregnancies, yet it represents 15% of all maternal-fetal 
morbidity and mortality.   According to the Centers of 
Disease Control and Prevention, in 2005, 623 women in 
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the United States died due to maternal causes.  Fifty of 
these deaths were linked to preeclampsia and eclamp-
sia [1].  Of the 14 maternal deaths reviewed in Iowa 
from 2004-2007, 3 were from complications of pre- 
eclampsia.  In addition, there is an increasing amount 
of data suggesting that preeclampsia is an early mark-
er for future cardiovascular disease in women [2-4]. 
During the Iowa Statewide Perinatal Team hospital visits we often review records of patients who are diagnosed with preeclampsia.  We have chosen to 
readdress the topic of preeclampsia; diagnosis and management in this issue of the Perinatal Letter.  Unfortunately space limitations prevent a more thor-
ough discussion but we hope the main points will be adequately addressed.
Preeclampsia/Eclampsia: An Immediate and Long Term Problem
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Recent data suggests that the sequelae of PreE such as 
fetal growth restriction may also predispose a fetus to 
long term consequences such as metabolic syndrome, 
hypertension, and infertility if the fetus survives into 
adulthood [5, 6].  Clearly, preeclampsia has immedi-
ate and potentially long term effects on both the fetus 
and mother.  Yet to date, the pathogenesis and cure of 
preeclampsia, is largely unknown.  Unfortunately it 
is currently not possible to predict who will develop 
PreE using laboratory, physiologic or ultrasound tests, 
therefore clinical risk factors remain the only predic-
tive tool.  Risk factors for PreE include past obstetrical 
history of PreE, first pregnancy, a family history, mul-
tiple gestation, obesity, preexisting hypertension, renal 
disease or collagen vascular disease, the antiphospho-
lipid syndrome, advanced maternal age and a pro-
longed interval between pregnancies.  Interestingly, 
tobacco smoking lowers the risk of preeclampsia by 
30-50%.  Although patients should obviously not be 
encouraged to smoke, there is ongoing research to help 
explain this phenomenon. 
Diagnosis of Preeclampsia: Clinical and  
Laboratory Manifestations
The diagnosis of preeclampsia is made when a preg-
nant woman has a persistently elevated blood pressure 
of 140 mm Hg systolic or higher or 90 mm Hg diastolic 
or higher that occurs after 20 weeks of gestation on 2 
occasions 6 hours apart (in a woman with previously 
normal blood pressures).  Hypertension is generally 
the earliest clinical finding of preeclampsia and is the 
most common clinical clue to the presence of the dis-
ease.  In addition to hypertension, proteinuria (defined 
as > 0.3 g protein in a 24 hour urine specimen) must 
be present in most cases to make the diagnosis of pre-
eclampsia.  In general, it is not necessary to repeat a 24 
hour urine collection later in pregnancy once the cri-
terion for proteinuria is met.  In a patient who has a 
condition with baseline proteinuria, a repeat 24 urine 
collection for protein concentration may be necessary 
to determine the diagnosis of PreE. However, it must 
be remembered that 20 percent of women who de-
velop eclampsia have no proteinuria and 10 percent of 
women who develop other clinical and/or histological 
findings of preeclampsia have no proteinuria.  There-
fore preeclampsia should be suspected in any pregnant 
woman with hypertension and characteristic signs/
symptoms, even in the absence of proteinuria.  
Preeclampsia can affect multiple organ systems 
and therefore can be associated with many other signs 
and symptoms.  Findings indicative of renal involve-
ment other than proteinuria include elevated serum 
creatinine, elevated serum uric acid levels and oliguria 
(< 500 mL in 24 hours).  Renal failure is a rare compli-
cation that can occur in patients with severe disease. 
The clinical manifestations of liver involvement in-
clude right upper quadrant or epigastric pain, elevated 
transaminases and, in the most severe cases, subcap-
sular hemorrhage or hepatic rupture, which may rep-
resent HELLP (Hemolysis, Elevated Liver transami-
nases, and Low Platelets) syndrome.  Central nervous 
system manifestations of preeclampsia include head-
ache, blurred vision, scotomata, and rarely cortical 
blindness.  Seizures in a woman with preeclampsia sig-
nify a change in diagnosis to eclampsia.  Stroke lead-
ing to death or disability is the most serious central 
nervous system complication of severe preeclampsia/
eclampsia.  Hemolysis and thrombocytopenia are the 
most common hematologic findings in preeclampsia. 
The PT, PTT and fibrinogen concentration are typi-
cally not affected unless there are additional compli-
cations, such as placental abruption or severe liver 
involvement.  Pulmonary edema can also be seen in 
preeclampsia.  Given the potential of preeclampsia to 
affect these many organ systems laboratory evaluation 
should include a complete blood count, quantification 
of urinary protein excretion in a 24 hour sample, serum 
creatinine concentration, and serum alanine and aspar-
tate aminotransferase concentrations (ALT and AST). 
Coagulation function tests are usually normal unless 
there is liver dysfunction or thrombocytopenia.  The 
fetal consequences of preeclampsia include growth re-
striction and oligohydramnios and are usually the re-
sult of chronic placental hypoperfusion.  Many of these 
examples of end organ damage help distinguish mild 
preeclampsia from severe preeclampsia.  
As preeclampsia can affect so many different or-
gan systems it is important to keep in mind the many 
mimickers of preeclampsia, such as different forms 
of thrombocytopenia, exacerbations of systemic lu-
pus erythematosus, cerebral vascular accidents, mi-
graine headaches, and liver disease such as hepatitis, 
cholestatsis and acute fatty liver of pregnancy.  These 
mimickers of preeclampsia underscore the importance 
of obtaining baseline lab values in those patients with 
preexisting conditions such as chronic hypertension 
or diabetes where proteinuria may exist prior to preg-
nancy.
On the other hand, preeclampsia can mimic many 
other diseases such as flu, gallbladder disease, mi-
graine headache etc. that may delay the diagnosis of 
preeclampsia.  A delay in diagnosis of preeclampsia has 
had lethal consequences for both the fetus and mother. 
Therefore in the face of a pregnant patient with hyper-
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tension and proteinuria, the patient has preeclampsia 
until proven otherwise.  
The diagnosis of preeclampsia is therefore largely 
based upon the characteristic clinical and laboratory 
features described above which develops after 20 
weeks of gestation in a woman who was previously 
normotensive.  Preeclampsia is classified as either 
mild or severe.  Findings indicative of severe disease 
are listed in Table 1.  The distinction between mild and 
severe preeclampsia is crucial as it has important rami-
fications on clinical management.  
It is important to remember that preeclampsia is 
part of a spectrum of disease that encompasses all hy-
pertension in pregnancy (see Table 2).  Clinical and 
laboratory findings are used to differentiate gesta-
tional hypertension and chronic hypertension and pre-
eclampsia, but signs and symptoms of these disorders 
often overlap.    
Management and Treatment of Preeclampsia
The initial management goal is to support the di-
agnosis by excluding other disorders characterized by 
hypertension and proteinuria.  The secondary goal is to 
assess the severity of disease, whether mild or severe. 
Laboratory evaluation helps to determine disease se-
verity by characterizing the extent of end organ in-
volvement.  Fetal well-being is evaluated by nonstress 
test and/or biophysical profile, ultrasound to evaluate 
fetal growth, amniotic fluid and if possible umbilical 
artery Doppler velocimetry.  
Table 1.  Criteria for Severe Preeclampsia
1.  Severe Blood Pressure Elevation (SBP > 160 mmHg of DBP > 110 mmHg on two occasions at least six hours 
apart)
2.  Proteinuria (5 or more grams in 24 hours)
3.  Oliguria (< 500 ml in 24 hours)
4. Symptoms of central nervous system dysfunction (blurred vision, severe headache, altered mental 
status)
5.  Symptoms of liver capsule distention (right upper quadrant or epigastric pain, nausea, vomiting)
6.  Hepatocellular injury (elevated serum transaminases; ALT, AST)
7.  Severe fetal growth restriction
8.  Pulmonary edema or cyanosis
9.  Cerebral vascular accident
10.  Thrombocytopenia (Platelet count < 100,000 per cubic millimeter)
 
Table 2:  The Spectrum of Hypertension in Pregnancy 
 Chronic 
Hypertension 
Gestational 
Hypertension 
Mild PreE Severe 
PreE 
CHTN with 
superimposed
PreE  
HELLP 
Syndrome 
BP criteria 140/90 140/90 140/90 160/110 140/90 140/90, but 
HTN may be 
absent 
GA at Dx < 20 weeks > 20 weeks > 20 weeks > 20 weeks < 20 weeks < 20 weeks 
Proteinuria 
(300 mg / 24 
hour ) 
May have 
>300mg  
< 300 mg > 300 mg  > 5 g  > 500 mg > 500 mg 
Other Labs No criteria for 
HELLP 
No criteria 
for HELLP 
No criteria 
for HELLP 
No criteria 
for HELLP 
No criteria 
for HELLP 
Bili > 1.2 
mg/dl 
LDH > 600 
IU/L 
SGOT > 72 
IU/L 
Platelet < 
100K/mm3 
 
 
 
 
 
 
 
 
 
 
Table 2.  The Spectrum of Hypertension in Pregnancy
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Mild Preeclampsia
Delivery of the fetus and placenta is the only “cure” 
for preeclampsia.  The timing of delivery is based pre-
dominantly on gestational age and severity of pre- 
eclampsia.  The goal of antepartum, expectant manage-
ment of preeclampsia is to maximize fetal benefits in 
the in utero environment while minimizing the related 
preeclamptic morbidities.   The rationale for hospitaliza-
tion of preeclamptics is to allow for rapid intervention 
in the face of sudden disease progression.  Although 
there is some data arguing for outpatient management 
of preeclampsia, it is important to note that in these 
studies many of these women were diagnosed with 
gestational hypertension only [7].  At the University, 
we advocate the hospitalization of all preeclamptics 
until delivery given the risk of brisk disease progres-
sion.  While in the hospital, activity is not restricted. 
Complete bedrest is not recommend as there are no 
published studies suggesting any improved outcome 
in preeclamptics in the face of increased risk for throm-
boembolism.  Inpatient, expectant management of all 
types of preeclampsia should include frequent blood 
pressure measurements, at least every 4 to 8 hours, ma-
ternal symptoms and re-checking of laboratory values 
with any change in maternal signs or symptoms.  The 
frequency and type of fetal surveillance depends on 
the type and severity of preeclampsia.  Although there 
is no agreement on the appropriate surveillance sched-
ule, most experts suggest NSTs 1-2 times per week 
from the time of diagnosis to time of delivery.  Increas-
ing frequency of surveillance may occur in the face of 
IUGR, non reassuring fetal status, abnormal Doppler 
studies, or worsening maternal status.  Amniotic fluid 
index and umbilical artery doppler studies should be 
performed with growth ultrasounds as a minimum. 
Twice weekly AFI and umbilical artery doppler studies 
should be performed in the face of oligohydramnios 
or abnormal growth.  These studies can help guide the 
timing of delivery.
Indications for delivery of a mild preeclamptic de-
pends on gestational age.  Any patient diagnosed with 
preeclampsia who is at 37 weeks or greater, should be 
delivered.  Attempted vaginal delivery is desired and 
appropriate in most cases where contraindications for 
a vaginal delivery do not exist.  A mild preeclamptic 
should be delivered at 34 weeks in the face of IUGR, 
abnormal fetal testing, PPROM or increasing signs and 
symptoms of severe preeclampsia.  The management 
and delivery of a mild preeclamptic at 36 weeks or be-
yond can in most instances be performed in a level I 
hospital if there is no evidence of worsening disease 
or fetal abnormalities.  Otherwise, consideration for 
transferring the patient to a level II or level III hospital 
may be most appropriate (see Figure 1).  
Figure 1.  Management of Mild Preeclampsia
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Severe Preeclampsia
The antepartum and intrapartum management of 
severe preeclampsia should be managed at a level II 
or level III facility whenever possible, especially when 
complex fetal abnormalities (i.e., severe IUGR, umbili-
cal artery doppler abnormalities) are present and the 
diagnosis occurs remote from term (< 32 weeks).  Ex-
pectant management of severe preeclampsia should 
only take place in a facility where there is immediate 
access to anesthesia given the elevated risk for eclamp-
sia and severe placental abruption.  The decision to de-
liver depends on the severity of concurrent conditions. 
Prompt delivery should be considered if the patient 
has conditions like eclampsia, abruption, HELLP syn-
drome or non-reassuring fetal status.  It is important 
to note that a “prompt delivery” does not necessarily 
mean a cesarean delivery.  To date, there are no data 
that support routine cesarean section for severe preec-
lampsia.  The decision to perform a cesarean section 
should be based on gestational age, fetal well being, 
and bishop score.  When the gestational age is signifi-
cantly preterm, delivery may be delayed for 24 to 48 
hours to allow for the administration of steroids in se-
lect cases.  When the diagnosis of severe preeclamp-
sia is made at less than 23 weeks, termination of preg-
nancy should be offered.  If this diagnosis is made in 
the late first trimester, there is increasing concern for a 
molar pregnancy requiring dilation and curettage.  The 
decision to deliver a patient at 23-32 weeks with severe 
preeclampsia should be based on worsening fetal or 
maternal status.  By 34 weeks, all severe preeclamptics 
should be delivered (see Figure 2).
Figure 2.  Management of Severe Preeclampsia
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Medications
The following section briefly discusses medications 
commonly used in the management of preeclampsia.
i.  Antihypertensives
 As a group, antihypertensives decrease the rate of 
severe hypertension in mild to moderate hyperten-
sive parturients, but do not decrease the progression 
to preeclampsia.  In addition, there is no significant 
difference in those treated with antihypertensives ver-
sus controls in perinatal mortality, preterm birth, and 
incidence of small for gestational age babies [8].  In 
acute severe hypertension, the treatment of elevated 
blood pressures serves to prevent cardiovascular and 
cerebrovascular complications.  Although a strict defi-
nition of sustained acute severe hypertension has not 
been delineated, experts argue that a systolic blood 
pressure in excess of 160-180 mmHg, diastolic blood 
pressure greater than 105-110 mmHg, or a mean arte-
rial blood pressure of above 130 mmHg on multiple 
exams necessitates treatment.
 Hydralazine is a common drug used for the treat-
ment of severe hypertension in pregnancy.   Intrave-
nous bolus injections of 5 to 10 mg may be adminis-
tered every 15 to 20 minutes for a maximum dose of 
20 mg.  IV labetalol is also commonly used.  It may be 
administered 20 to 40 mg intravenously every 10 to 15 
minutes for a maximum dose of 220 mg.  Oral nife-
dipine is another alternative for the treatment of severe 
hypertension.  It is dosed at 10-20 mg every 30 minutes 
for a maximum dose of 50 mg.  Other antihyperten-
sives such as nimodipine have also been evaluated for 
use in severe hypertension.  To date, there has not been 
any reliable evidence to assert any conclusions about 
the comparative effects of any of these drugs [9].   At 
the University of Iowa, intravenous labetalol or hy-
dralazine are the drugs of choice for the treatment of 
sustained acute severe hypertension.
ii.  Magnesium Sulfate and Anti-eclampsia  
Medications
 One success in the medical treatment of preeclamp-
sia is magnesium sulfate.  Magnesium sulfate decreas-
es the risk of eclamptic seizures.  This rate may be de-
creased  by over 60 percent in the postpartum period 
[10].  Magnesium should be initiated at the onset of 
labor and maintained in the postpartum period.  There 
is some controversy in the literature debating which 
preeclamptic patients should receive postpartum mag-
nesium and for how long.  Some studies would argue 
that mild preeclamptics do not require postpartum 
magnesium.  Other studies have published diuresis 
criteria for the discontinuation of postpartum magne-
sium in mild and severe preeclamptics [11,12].  At the 
University of Iowa, patients with severe preeclampsia 
receive postpartum magnesium for at least 24 hours. 
In contrast, postpartum magnesium is discontinued in 
less than 24 hours in mild preeclamptics if the patient 
has a urine output of greater than or equal to 200 cc/
hour for 4 consecutive hours.
 In the setting of an acute ecclamptic event magne-
sium sulfate is still the drug of choice in the treatment 
of the seizure.  Magnesium is administered 4-6 mg IV 
over 15-20 minutes.  The dose may be repeated in the 
face of a repeat seizure.  If a patient has recalcitrant 
seizure activity, diazepam 10mg IV may also be admin-
istered.  Serum magnesium sultate levels may need to 
be monitored, especially in the setting of oliguria.
 Remember, in the setting of preeclampsia magne-
sium sulfate is administered as a seizure prophylaxis. 
Any patient receiving magnesium sulfate for this pur-
pose should be confined to bed (i.e., no ambulation or-
ders, including bathroom), a foley catheter should be 
place so accurate hourly I/O’s can be calculated, and 
the patient should be NPO, except for sips H2O and 
ice chips, to minimize complications of aspiration if a 
seizure occurs.
iii.  Steroids and Tocolytics
If the maternal and fetal clinical situation allows for 
expectant management, antenatal corticosteroids (be-
tamethasone) should be administered to promote fetal 
lung maturity to women less than 34 weeks of gesta-
tion since preterm delivery is common.  
Conclusions
Clearly, there is a need for more study to improve 
the prediction and prevention of preeclampsia.  There 
are some successes in the management of preeclamp-
sia.  This management is dictated predominantly by 
the gestational age at diagnosis and the severity of dis-
ease.  Yet, one of the most important considerations in 
treating preeclampsia is access to anesthesia and ap-
propriate postpartum care for both the mother and the 
infant.
In summary I will address, by bullet points, the 
take-home points.
•	 Any	pregnant	woman	with	complaints	that	can	be	
consistent with preeclampsia should be taken seri-
ously and the diagnosis of preeclamopsia needs to 
be ruled out.
•	 The	diagnosis	 of	 preeclampsia	 should	be	made	 in	
any pregnant woman who meets blood pressure 
and proteinuria criteria (140/90 on two separate oc-
casions at least 6 hour apart and >300 mg/dl uri-
nary protein on a 24 hour collection) after 20 weeks 
who was previously normotensive.
•	 There	is	usually	no	need	to	repeat	24	hour	urines	af-
ter the diagnosis of preeclampsia is made.  A change 
in management plan is rarely affected by an increase 
in proteinuria without any other changes.
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•	 We	believe	that	all	women	who	are	given	a	diagno-
sis of preeclampsia should be hospitalized for the 
duration of their pregnancies.
•	 All	mild	preeclamptic	patients	should	be	delivered	
by 37 weeks.  All women with severe preeclampsia 
should be delivered by 34 weeks, sooner if clinical 
condition warrants.  
•	 We	 believe	 all	 women	 who	 are	 diagnosed	 with	
preeclampsia should receive intrapartum and post-
partum magnesium sulfate.  The duration of admin-
istration is discussed in the text.
•	 Any	woman	with	preeclampsia	who	 is	on	magne-
sium sulfate should be confined to bed with a foley 
catheter in place. (We have seen instances where 
patients are allowed to ambulate or have bathroom 
privileges.  Remember they are receiving magne-
sium sulfate as a seizure prophylaxis, you would not 
want a patient to have a seizure in the bathroom.)
•	 Similarly,	 any	 woman	 with	 preeclampsia	 who	 is	
on magnesium sulfate should be NPO except for 
ice chips/sips of water.  Aspiration is a significant 
risk with a seizure.  We have seen several instances 
around the state where patients are allowed a gener-
al diet while receiving magnesium sulfate therapy.
 —Mark Santillan, MD 
Maternal-Fetal Medicine Fellow Associate 
Obstetrics and Gynecology 
University of Iowa Hospitals and Clinics
—Stephen K. Hunter, MD, PhD 
Maternal-Fetal Medicine Specialist 
Obstetrics and Gynecology 
University of Iowa Hospitals and Clinics 
Associate Director, Statewide Perinatal 
Care Program
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